These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

715 related items for PubMed ID: 28292274

  • 1. Significance of clinical and morphological prognostic risk factors in IgA nephropathy: follow-up study of comparison patient groups with and without renoprotection.
    Riispere Ž, Kuudeberg A, Seppet E, Sepp K, Ilmoja M, Luman M, Kõlvald K, Auerbach A, Ots-Rosenberg M.
    BMC Nephrol; 2017 Mar 14; 18(1):89. PubMed ID: 28292274
    [Abstract] [Full Text] [Related]

  • 2. Fractional urinary excretion of IgG is the most powerful predictor of renoprotection by ACE inhibitors in IgA nephropathy.
    Bazzi C, Rizza V, Paparella M, Casellato D, Napodano P, Olivieri G, D'Amico G.
    J Nephrol; 2009 Mar 14; 22(3):387-96. PubMed ID: 19557716
    [Abstract] [Full Text] [Related]

  • 3. IgA nephropathy clinicopathologic study following the Oxford classification: Progression peculiarities and gender-related differences.
    Riispere Ž, Laurinavičius A, Kuudeberg A, Seppet E, Sepp K, Ilmoja M, Luman M, Kõlvald K, Auerbach A, Ots-Rosenberg M.
    Medicina (Kaunas); 2016 Mar 14; 52(6):340-348. PubMed ID: 27932191
    [Abstract] [Full Text] [Related]

  • 4. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
    Manno C, Torres DD, Rossini M, Pesce F, Schena FP.
    Nephrol Dial Transplant; 2009 Dec 14; 24(12):3694-701. PubMed ID: 19628647
    [Abstract] [Full Text] [Related]

  • 5. Long-term beneficial effects of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy for patients with advanced immunoglobulin A nephropathy and impaired renal function.
    Moriyama T, Amamiya N, Ochi A, Tsuruta Y, Shimizu A, Kojima C, Itabashi M, Takei T, Uchida K, Nitta K.
    Clin Exp Nephrol; 2011 Oct 14; 15(5):700-707. PubMed ID: 21625892
    [Abstract] [Full Text] [Related]

  • 6. Effect of hematuria on the outcome of IgA nephropathy with mild proteinuria.
    Tanaka K, Moriyama T, Iwasaki C, Takei T, Nitta K.
    Clin Exp Nephrol; 2015 Oct 14; 19(5):815-21. PubMed ID: 25475403
    [Abstract] [Full Text] [Related]

  • 7. The effect of renin-angiotensin system blockade on the incidence of end-stage renal disease in IgA nephropathy.
    Tanaka S, Ninomiya T, Katafuchi R, Masutani K, Nagata M, Tsuchimoto A, Hirakata H, Kitazono T, Tsuruya K.
    Clin Exp Nephrol; 2016 Oct 14; 20(5):689-698. PubMed ID: 26564155
    [Abstract] [Full Text] [Related]

  • 8. Retrospective Analysis of Clinical Outcomes in Patients with Immunoglobulin A Nephropathy and Persistent Hematuria Following Renin-Angiotensin System Blockade.
    Chen J, Liu S, Xu H, Wang W, Xie Y, Tang W, Yuan Q, Zheng L, Lin L, Fu S, Shen J.
    Med Sci Monit; 2020 Aug 21; 26():e922839. PubMed ID: 32822333
    [Abstract] [Full Text] [Related]

  • 9. The beneficial effects of renin-angiotensin system inhibitors (RASI) on IgA nephropathy with tubulointerstitial lesions categorized by Oxford classification.
    Kamiyama T, Moriyama T, Kumon S, Karasawa K, Nitta K.
    Clin Exp Nephrol; 2019 Jun 21; 23(6):834-840. PubMed ID: 30796546
    [Abstract] [Full Text] [Related]

  • 10. The correlation analysis between the Oxford classification of Chinese IgA nephropathy children and renal outcome - a retrospective cohort study.
    Wu H, Xia Z, Gao C, Zhang P, Yang X, Wang R, Wang M, Peng Y.
    BMC Nephrol; 2020 Jul 01; 21(1):247. PubMed ID: 32611399
    [Abstract] [Full Text] [Related]

  • 11. Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort.
    Coppo R, Lofaro D, Camilla RR, Bellur S, Cattran D, Cook HT, Roberts IS, Peruzzi L, Amore A, Emma F, Fuiano L, Berg U, Topaloglu R, Bilginer Y, Gesualdo L, Polci R, Mizerska-Wasiak M, Caliskan Y, Lundberg S, Cancarini G, Geddes C, Wetzels J, Wiecek A, Durlik M, Cusinato S, Rollino C, Maggio M, Praga M, K Smerud H, Tesar V, Maixnerova D, Barratt J, Papalia T, Bonofiglio R, Mazzucco G, Giannakakis C, Soderberg M, Orhan D, Di Palma AM, Maldyk J, Ozluk Y, Sudelin B, Tardanico R, Kipgen D, Steenbergen E, Karkoszka H, Perkowska-Ptasinska A, Ferrario F, Gutierrez E, Honsova E.
    Pediatr Nephrol; 2017 Jan 01; 32(1):139-150. PubMed ID: 27557557
    [Abstract] [Full Text] [Related]

  • 12. Predictors of Progression in IgA Nephropathy in Childhood.
    Mizerska-Wasiak M, Małdyk J, Turczyn A, Cichoń-Kawa K, Rybi-Szumińska A, Wasilewska A, Bieniaś B, Zajączkowska M, Miklaszewska M, Pietrzyk J, Demkow U, Roszkowska-Blaim M, Pańczyk-Tomaszewska M.
    Adv Exp Med Biol; 2017 Jan 01; 955():65-73. PubMed ID: 27718216
    [Abstract] [Full Text] [Related]

  • 13. Tacrolimus improves the proteinuria remission in patients with refractory IgA nephropathy.
    Zhang Q, Shi SF, Zhu L, Lv JC, Liu LJ, Chen YQ, Zhang H, Wang HY.
    Am J Nephrol; 2012 Jan 01; 35(4):312-20. PubMed ID: 22456060
    [Abstract] [Full Text] [Related]

  • 14. Comparison of inhibitors of renin-angiotensin-aldosterone system (RAS) and combination therapy of steroids plus RAS inhibitors for patients with advanced immunoglobulin A nephropathy and impaired renal function.
    Moriyama T, Nakayama K, Ochi A, Amemiya N, Tsuruta Y, Kojima C, Itabashi M, Takei T, Uchida K, Nitta K.
    Clin Exp Nephrol; 2012 Apr 01; 16(2):231-7. PubMed ID: 22038185
    [Abstract] [Full Text] [Related]

  • 15. Progression of IgA nephropathy under current therapy regimen in a Chinese population.
    Li X, Liu Y, Lv J, Shi S, Liu L, Chen Y, Zhang H.
    Clin J Am Soc Nephrol; 2014 Mar 01; 9(3):484-9. PubMed ID: 24408121
    [Abstract] [Full Text] [Related]

  • 16. Clinical and histopathologic profile of patients with primary IgA nephropathy seen in a tertiary hospital in India.
    Bagchi S, Singh G, Yadav R, Kalaivani M, Mahajan S, Bhowmik D, Dinda A, Agarwal SK.
    Ren Fail; 2016 Mar 01; 38(3):431-6. PubMed ID: 26837482
    [Abstract] [Full Text] [Related]

  • 17. Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study.
    Tesar V, Troyanov S, Bellur S, Verhave JC, Cook HT, Feehally J, Roberts IS, Cattran D, Coppo R, VALIGA study of the ERA-EDTA Immunonephrology Working Group.
    J Am Soc Nephrol; 2015 Sep 01; 26(9):2248-58. PubMed ID: 25677392
    [Abstract] [Full Text] [Related]

  • 18. Intrarenal Arterial Lesions Are Associated with Higher Blood Pressure, Reduced Renal Function and Poorer Renal Outcomes in Patients with IgA Nephropathy.
    Zhang Y, Sun L, Zhou S, Xu Q, Xu Q, Liu D, Liu L, Hu R, Quan S, Xing G.
    Kidney Blood Press Res; 2018 Sep 01; 43(2):639-650. PubMed ID: 29698975
    [Abstract] [Full Text] [Related]

  • 19. Increased Serum IgA in Children with IgA Nephropathy, Severity of Kidney Biopsy Findings and Long-Term Outcomes.
    Mizerska-Wasiak M, Małdyk J, Pańczyk-Tomaszewska M, Turczyn A, Cichoń-Kawa K, Rybi-Szumińska A, Wasilewska A, Firszt-Adamczyk A, Stankiewicz R, Bieniaś B, Zajączkowska M, Gadomska-Prokop K, Grenda R, Miklaszewska M, Pietrzyk J, Pukajło-Marczyk, Zwolińska D, Szczepańska M, Demkow U, Roszkowska-Blaim M.
    Adv Exp Med Biol; 2015 Sep 01; 873():79-86. PubMed ID: 26269025
    [Abstract] [Full Text] [Related]

  • 20. Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial.
    Ferraro PM, Ferraccioli GF, Gambaro G, Fulignati P, Costanzi S.
    Nephrol Dial Transplant; 2009 Jan 01; 24(1):156-60. PubMed ID: 18685141
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.